- PR Newswire•12 days ago
CAMBRIDGE, Mass., Feb. 13, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) today announced that Jeffery Kutok, M.D., Ph.D. has been promoted to the role of chief scientific officer, effective immediately. In this role, Dr. Kutok will be responsible for overseeing biology and translational science efforts, including preclinical collaborations, to support the ongoing clinical development of IPI-549, Infinity's oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma).
- PR Newswire•19 days ago
CAMBRIDGE, Mass., Feb. 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the 2017 BIO CEO & Investor Conference in New York City on Monday, February 13, 2017. ...
- Accesswire•23 days ago
NEW YORK, NY / ACCESSWIRE / February 2, 2017 / The Biotech Industry has performed admirably in 2017, despite the negative attention drug makers have been receiving. The iShares NASDAQ Biotechnology Index ...
INFI : Summary for Infinity Pharmaceuticals, Inc. - Yahoo Finance
Infinity Pharmaceuticals, Inc. (INFI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.01 x 2200|
|Day's Range||2.10 - 2.31|
|52 Week Range||0.84 - 6.97|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|